Top Breast Cancer Researcher Didn’t Disclose Financial Ties

José Baselga of Memorial Sloan Kettering took millions of dollars from drug and health care companies but did not report the payments in his research articles.

Written byAshley Yeager
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: WIKIMEDIA, JULIANA THOMAS

Update (September 14): Cancer researcher José Baselga resigned yesterday from Memorial Sloan Kettering following reports of his failure to disclosure payments from health care companies, The New York Times reports.

Since 2013, José Baselga, a world-renowned cancer researcher at the Memorial Sloan Kettering Cancer Center, has received millions of dollars from drug and health care companies but has not disclosed the financial connections in research articles, according to an investigation by The New York Times and Pro Publica published Saturday (September 8).

One of the most flagrant omissions was Baselga’s failure to follow the rules of disclosure from the American Association for Cancer Research, even when he served as president of the organization. The association puts out Cancer Discovery, a journal in which Baselga published without declaring the payments he received. He also served as the journal’s editor-in-chief at the time.

Another major lapse, according to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies